Quick Answer
INTERPACE BIOSCIENCES, INC. reported Total Revenue of $38.73 million for fiscal year 2025.
INTERPACE BIOSCIENCES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $38.73M -17.5% |
$46.93M +17.2% |
$40.04M +25.7% |
$31.84M -3.9% |
$33.12M +2.2% |
$32.40M +33.8% |
| Revenue (ASC 606) | $38.73M -17.5% |
$46.93M +17.2% |
$40.04M +25.7% |
$31.84M -3.9% |
$33.12M +2.2% |
$32.40M +33.8% |
| Net Income | $24.57M +266.7% |
$6.70M +243.0% |
$1.95M +108.9% |
-$21.96M -46.9% |
-$14.94M +43.5% |
-$26.45M +1.1% |
| Diluted EPS | $0.89 +122.5% |
$0.40 -11.1% |
$0.45 +108.7% |
-$5.18 | — | — |
| Total Assets | $33.84M +178.7% |
$12.14M -24.0% |
$15.98M +0.0% |
$15.98M -58.4% |
$38.43M -15.9% |
$45.68M -11.4% |
| Cash and Equivalents | $2.50M -10.9% |
$2.81M -49.7% |
$5.60M +15.9% |
$4.83M +80.7% |
$2.67M -3.6% |
$2.77M +19.4% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $22.36M +140.8% |
-$54.77M +4.6% |
-$57.39M +1.2% |
-$58.09M -36.9% |
-$42.42M -289.2% |
-$10.90M |
| R&D Expense | $642.0K -5.0% |
$676.0K +6.3% |
$636.0K -9.5% |
$703.0K -52.9% |
$1.49M -46.6% |
$2.79M -0.5% |
| Operating Income | $4.08M -49.6% |
$8.11M +105.0% |
$3.96M +209.4% |
-$3.62M +42.9% |
-$6.34M +75.7% |
-$26.07M +1.4% |
| Gross Profit | $24.13M -19.4% |
$29.93M +19.4% |
$25.06M +37.4% |
$18.23M -3.0% |
$18.80M +75.3% |
$10.72M +28.7% |
| Shares Outstanding | 4.43M +1.2% |
4.38M +1.5% |
4.31M +0.3% |
4.30M +2.4% |
4.20M +3.4% |
4.06M +3.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $8.76M | -28.8% | -5.2% |
| Revenue (ASC 606) | September 30, 2025 | $8.76M | -28.8% | -5.2% |
| Net Income | September 30, 2025 | $911.0K | -45.6% | +242.3% |
| Diluted EPS | September 30, 2025 | $0.03 | -92.1% | +121.4% |
| Total Assets | September 30, 2025 | $12.04M | -14.3% | -2.4% |
| Cash and Equivalents | October 31, 2025 | $2.10M | — | +47.6% |
| Long-Term Debt | March 31, 2017 | $4.36M | -28.9% | -44.8% |
| Stockholders Equity | September 30, 2025 | -$298.0K | +99.4% | +75.4% |
| R&D Expense | September 30, 2025 | $150.0K | -24.6% | -13.3% |
| Operating Income | September 30, 2025 | $1.15M | -50.2% | +344.7% |
| Gross Profit | September 30, 2025 | $5.44M | -31.2% | +3.1% |
| Shares Outstanding | September 30, 2025 | 4.43M | +0.5% | +0.1% |
- INTERPACE BIOSCIENCES, INC. reported Total Revenue of $38.73 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed a decrease of -17.5% in Total Revenue compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Revenue (ASC 606) of $38.73 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed a decrease of -17.5% in Revenue (ASC 606) compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Net Income of $24.57 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed an increase of +266.7% in Net Income compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Diluted EPS of $0.89 per share for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed an increase of +122.5% in Diluted EPS compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Total Assets of $33.84 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed an increase of +128.8% in Total Assets compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Cash and Equivalents of $2.50 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed an increase of +71.5% in Cash and Equivalents compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Long-Term Debt of $7.91 million for fiscal year 2016.
- INTERPACE BIOSCIENCES, INC. showed an increase of +9.3% in Long-Term Debt compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Stockholders Equity of $22.36 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed an increase of +1108.7% in Stockholders Equity compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported R&D Expense of $642.0 thousand for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed a decrease of -5.0% in R&D Expense compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Operating Income of $4.08 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed a decrease of -49.6% in Operating Income compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Gross Profit of $24.13 million for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed a decrease of -19.4% in Gross Profit compared to the prior fiscal year.
- INTERPACE BIOSCIENCES, INC. reported Shares Outstanding of 4.43 million shares for fiscal year 2025.
- INTERPACE BIOSCIENCES, INC. showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: